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The 4th International Conference on Gold and Silver in Medicine was held at the University of Wisconsin,
Milwaukee, May 31 - June 1 1998, in conjunction with the 31st Great Lakes Regional American Chemical
Society Meeting. The highlights are summarized here.
The meeting was organized and hosted by Professor C
Frank Shaw III of the Chemistry Department at
UWM and was sponsored by the Gold and Silver
Institutes, both of Washington, DC. This meeting
brought together scientists from a diversity of
disciplines including synthetic and structural
chemistry, tumour biology, microbiology and
immunology. All of the participants shared a common
interest and enthusiasm, ie the medical uses of gold
and silver.
The interdisciplinary and international content of
the meeting was immediately in evidence with the
opening talk given by Sue Berners-Price (Griffith
University, Australia) on the selective antitumour
activity of gold and silver complexes of bidentate
pyridylphosphine (RzP(CHz)zPRz where R = 2-
pyridyl, 3-pyridyl, and -l-pyrtdyl). These compounds
are hydrophobic cations and were investigated
following the observation that the uptake of
hydrophobic cations is greater in tumours than normal
tissue. The goldll) 4-pyridyl derivative was found to be
active against a cisplatin-resistant ovarian tumour cell
line, and to have in vivo activity against the colon 38
tumour. Parish (UMIST, UK) also addressed the
antitumour activity of gold complexes and discussed
the rationale for the use of gold(III) complexes as
potential antitumour drugs. In a biological
environment Au (III) is readily reduced to Au (I). In
order to counteract this, a group of stable Au (III)
dimethylbenzylamine derivatives was synthesized, and
their biological activity against microorganisms and
mammalian cell lines investigated. A screening strategy
for metal-based anticancer drugs was described by
Fricker (AnorMED, Canada) utilizing an in vitro panel
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of human tumour cell lines which could also be grown
as xenografted solid tumours in immune-deprived
mice. In collaboration with Parish, this methodology
was used to demonstrate the antitumour activity of the
Au(III) dimethylbenzylamine complexes. Furthermore,
mechanistic studies were able to show that these
compounds possess a mechanism of action different
from that of the Pt(II) antitumour drugs such as
cisplatin. Boron neutron capture therapy is an
experimental radiotherapy technique for treating brain
tumours. Laguna (Universidad de Zaragoza, Spain)
described the synthesis of ortho-carborane (1,2-
dicarbo-closo-dodecaborane) derivatives of gold and
silver with high coordination numbers. The ability to
incorporate high concentrations of boron atoms into
the molecule makes these derivatives suitable
candidates for boron neutron capture therapy.
Chrysotherapy, utilizing Au (I) thiolates, is used by
physicians for the treatment of rheumatoid arthritis.
This is an autoimmune disease, and a number of
speakers discussed the interaction of gold compounds
with the immune system. One of the most interesting
recent discoveries on the mechanism of action of these
drugs is their apparent ability to inhibit transcription
of genes whose products are key components of the
immune response. Dicyanogold, a major metabolite of
the Au(I) thiolates, was shown to inhibit transcription
of the cytokines Interleukin-2 and Interleukin-l [).
Tepperman (Cincinatti, USA) postulated that the
molecular target was the transcription factor AP-l. An
alternative mechanism that has been proposed for the
action the antiarthritic gold drugs is to control cell
damaging oxidants. The influence of ligand type and
coordination geometry upon the electronic structure of
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goldtl) complexes and their potential ability to remove
potent oxidants such as reactive oxygen species from
cells was investigated by Fackler (Texas, USA). The
importance of Au(CN)Z- was further elaborated by
Elder (Cincinatti, USA). This metabolite has been
shown to be an inhibitor of the reverse transcriptase of
HIY. The cellular targets for HIV are T lymphocytes,
and monocytes. It was shown that dicyanogold could
be taken up into the cytoplasm of the ]urkat T cell
line, bound to a protein of molecular weight 20kD.
Gold was also found in the cell nucleus, the
intracellular target for HIY. Some of the side effects of
the anti-arthritic gold drugs have been attributed to
the oxidation of Au (I) to Au (III). Best (London, UK)
discussed this hypothesis and demonstrated the
interaction of [Au(dien) Cl] CIZ with model tripeptides,
Cly-Cly-gCy, Gly-Gly-His, and Val-Ile-His-Asn. It was
postulated that the formation of Au-His chelates
within peptides and proteins might be responsible for
the hypersensitivity reaction to Au (III). Shaw
(Wisconsin, USA) also described the immunological
response to gold-peptide complexes in the poster
session. In mice, Au (I) thiomalate inhibits T cell
recognition of a bovine insulin peptide, InsulinA 1-14.
This peptide was synthesized and characterized by 2D
1H - NMR, and the structure modelled using
molecular dynamics computations.
A number of speakers addressed the structural
aspects, and reactivity of gold complexes. By using
electrospray mass spectrometry Howard-Locke
(McMaster University, Canada) was able to show that
Au (I) sodium thiomalate exists as a cyclic tetramer
with the thiol ligands bridging pairs of gold atoms.
The gold (I) thiolate drugs can undergo ligand
exchange with naturally occurring thiols. The reactivity
of gold compounds with a variety of thiols was
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addressed by several speakers. The interaction of Au (I)
with disulfides such as cystine was postulated to be a
potentially important biochemical reaction for gold(I).
Alice Bruce (Maine, USA) presented studies on the
kinetics and mechanism of the substitution reactions of
dinuclear goldll) phosphine thiolate complexes such as
[Auz(dppm) (SC 6H4CH3)z] with the phenyldisulfide
(SC 6H4Cl)z as a model for the interaction of gold with
disulfides. The important factors in this reaction were
shown to be the electronic and steric properties of the
reactants, and the presence of an Au-Au bond. The
electronic structure of dinuclear gold (I) complexes
([Auz(dppee)Xz] where X = halide and dppee =
diphenylphosphinoethylene) was investigated by
Mitchell Bruce (Maine, USA) using quantum yield
measurements combined with electrochemical studies.
Garcia (Santiago de Compostela, Spain) examined the
different coordination modes of Au (I) and Ag(I) tripod
phosphine complexes, where tripod 1,1,1-
tris (diphenyphosphinomethyl) ethane. Crystal
structures of [Au3(tripod)Xz]X (where X=halide) were
obtained and geometries confirmed using 31p NMR.
There was also a series of interesting papers on the
medical uses of silver, and altogether this was a small,
highly focused meeting, bringing together experts in
the fields of bioinorganic chemistry and medicinal
uses of gold and silver, and providing an effective
update of the subject area. Professor Shaw is to be
congratulated on organizing a stimulating, and
successful meeting. We should all look forward with
anticipation to the 5th meeting. The full proceedings
of the 4th meeting are to be published in a special
edition of 'Metal-Based Drugs', and will be dedicated
to the memory of the late Professor Colin Locke, who
was a major contributor to the field, and previous
Gold and Silver meetings.
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